A phase 1, open-label study to determine safety and tolerability of the topical application of mesenchymal stem/stromal cell (MSC) exosome ointment to treat psoriasis in healthy volunteers - Chandran, Nisha Suyien; Bhupendrabhai, Monil Nagad; Tan, Thong Teck; Zhang, Bin; Lim, Sai Kiang; Choo, Andre Boon Hwa; Lai, Ruenn Chai (Cytotherapy (Oxford, England), 2025)
Keywords: Administration, Topical; Adult; Advanced Basic Science; COVID-19; Exosome; Exosomes - transplantation; Female; Healthy Volunteers; Humans; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - metabolism; Mesenchymal stem/stromal cells (MSCs); Middle Aged; Ointments - administration & dosage; Ointments - adverse effects; Other; Psoriasis; Psoriasis - therapy; Young Adult; SCORAD; Psoriasis; AE; FTU; IP; EOS; VAS; Mesenchymal stem/stromal cells (MSCs); IMQ; ICF; TID; ICH; SD; TEAE; Exosome; GCP; SAE; HAS; GRAS; MSC; CIOMS; CFB; End of Study; Imiquimod; Visual Assessment Score; Standard Deviation; Treatment-emergent Adverse Event; ter in die (thrice a day); Adverse Event; International Conference on Harmonization; Health Sciences Authority; Generally Recognized as Safe; Change from Baseline; Informed Consent Form; Scoring Atopic Dermatitis; Serious Adverse Event; Mesenchymal Stem/stromal Cell; Good Clinical Practice; Investigational Product; Council for International Organizations of Medical Sciences; Fingertip Unit